A novel approach to assess Lung Health

Functional Respiratory Imaging (FRI) is a imaging technology which enhances drug development and patient care by providing patient-specific parameters

How it works Patient-specific parameters

A novel approach to assess Lung Health

Functional Respiratory Imaging (FRI) is a imaging technology which enhances drug development and patient care by providing patient-specific parameters

How it works Patient-specific parameters

Patient-specific parameters

  • 3D visualization and quantification of patient’s airway and lung geometry on a regional, often lobar, level
  • Deposition characteristics of inhaled compounds

Patient-specific parameters

Patient-specific parameters

  • 3D visualization and quantification of patient’s airway and lung geometry on a regional, often lobar, level
  • Deposition characteristics of inhaled compounds

Patient-specific parameters

FRI benefits

Use in Clinical Trials

FRI reduces the cost and time required for screening most promising new respiratory drugs in early clinical phase

Use in Clinical Practice

FRI is sensitive and identifies more quickly inefficient therapies, improving patient care

FRI benefits

FRI benefits

Use in Clinical Trials

FRI reduces the cost and time required for screening most promising new respiratory drugs in early clinical phase

Use in Clinical Practice

FRI is sensitive and identifies more quickly inefficient therapies, improving patient care

FRI benefits

“FLUIDDA’s technique and insights to the subject were outstanding. We were delighted with the science and collaboration we had with FLUIDDA.“

Mark Milton – Edwards Global Dir. Respiratory, TEVA

“FLUIDDA’s technology is an important tool which helps bridge data from in vitro and in vivo studies.“

Dr. Paul M. Dorinsky – Head Global Respiratory Clinical Development, Cipla

“FLUIDDA’s technique and insights to the subject were outstanding. We were delighted with the science and collaboration we had with FLUIDDA.“

Mark Milton – Edwards Global Dir. Respiratory, TEVA

“FLUIDDA’s technology is an important tool which helps bridge data from in vitro and in vivo studies.“

Dr. Paul M. Dorinsky – Head Global Respiratory Clinical Development, Cipla

Fluidda at the ERS congress in Madrid: Visit Booth K.06

Still being built, but visit the Fluidda booth at the ERS congress, starting tomorrow in Madrid, to experience state of
Read More

Drug delivery to the lungs of asthmatic patients using Dry Powder Inhalers: device and formulation matters!

This study will be presented at ERS 2019 at a thematic poster session on Tuesday October 1st between 12.50 pm
Read More

Functional Respiratory Imaging (FRI) in combination with A.I. predicts early-life wildfire smoke exposure with accuracy and sensitivity in excess of 90%.

During the coming ERS conference ( Sept 29- Oct 2 in Madrid, Spain) Fluidda will present the results of a
Read More

Differences found in lung deposition of extrafine vs non-extrafine triple therapies in patients with COPD using FRI.

This study will be presented at ERS 2019 at a thematic poster session on Monday September 30 between 12.50 pm
Read More

All content © FLUIDDA 2019